Tackling EGFR signaling with TACE antagonists: a rational target for metalloprotease inhibitors in cancer

ISSN： 1472-8222

Source： Expert Opinion on Therapeutic Targets, Vol.11, Iss.10, 2007-10, pp. : 1287-1298

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rational Combination of Targeted Therapies As A Strategy to Overcome The Mechanisms of Resistance to Inhibitors of EGFR Signaling

Current Pharmaceutical Design, Vol. 13, Iss. 33, 2007-11 ,pp. : 3358-3367

Bentham Science Publishers

Access to resources Recommend Favorite

Emerging EGFR antagonists for breast cancer

By Lluch Ana Eroles Pilar Perez-Fidalgo Jose-Alejandro

Expert Opinion on Emerging Drugs, Vol. 19, Iss. 2, 2014-06 ,pp. : 165-181

Informa Healthcare

Access to resources Recommend Favorite

Clinical Potential of Matrix Metalloprotease Inhibitors in Cancer Therapy

By Heath E.I.

Drugs, Vol. 59, Iss. 5, 2000-05 ,pp. : 1043-1055

Adis International

Access to resources Recommend Favorite

New inhibitors of the mammalian target of rapamycin signaling pathway for cancer

By Albert Sébastien Serova Maria Dreyer Chantal Sablin Marie-Paule Faivre Sandrine Raymond Eric

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 8, 2010-08 ,pp. : 919-930

Informa Healthcare

Access to resources Recommend Favorite

Metalloprotease inhibitors

Expert Opinion on Therapeutic Patents, Vol. 8, Iss. 9, 1998-09 ,pp. : 1191-1194

Informa Healthcare

Access to resources Recommend Favorite